Alternatived Products of [ 42202-95-9 ]
Product Details of [ 42202-95-9 ]
| CAS No. : | 42202-95-9 | MDL No. : | MFCD02179417 |
| Formula : | C7H5ClFNO | Boiling Point : | - |
| Linear Structure Formula : | - | InChI Key : | - |
| M.W : | 173.57 | Pubchem ID : | - |
| Synonyms : |
Calculated chemistry of [ 42202-95-9 ] Expand+
Physicochemical Properties
| Num. heavy atoms : | 11 |
| Num. arom. heavy atoms : | 6 |
| Fraction Csp3 : | 0.0 |
| Num. rotatable bonds : | 1 |
| Num. H-bond acceptors : | 3.0 |
| Num. H-bond donors : | 1.0 |
| Molar Refractivity : | 40.58 |
| TPSA : | 32.59 Ų |
Pharmacokinetics
| GI absorption : | High |
| BBB permeant : | Yes |
| P-gp substrate : | No |
| CYP1A2 inhibitor : | No |
| CYP2C19 inhibitor : | No |
| CYP2C9 inhibitor : | No |
| CYP2D6 inhibitor : | No |
| CYP3A4 inhibitor : | No |
| Log Kp (skin permeation) : | -5.38 cm/s |
Lipophilicity
| Log Po/w (iLOGP) : | 1.8 |
| Log Po/w (XLOGP3) : | 2.79 |
| Log Po/w (WLOGP) : | 2.62 |
| Log Po/w (MLOGP) : | 2.36 |
| Log Po/w (SILICOS-IT) : | 2.46 |
| Consensus Log Po/w : | 2.4 |
Druglikeness
| Lipinski : | 0.0 |
| Ghose : | None |
| Veber : | 0.0 |
| Egan : | 0.0 |
| Muegge : | 1.0 |
| Bioavailability Score : | 0.55 |
Water Solubility
| Log S (ESOL) : | -3.01 |
| Solubility : | 0.169 mg/ml ; 0.000974 mol/l |
| Class : | Soluble |
| Log S (Ali) : | -3.13 |
| Solubility : | 0.128 mg/ml ; 0.00074 mol/l |
| Class : | Soluble |
| Log S (SILICOS-IT) : | -2.81 |
| Solubility : | 0.271 mg/ml ; 0.00156 mol/l |
| Class : | Soluble |
Medicinal Chemistry
| PAINS : | 0.0 alert |
| Brenk : | 3.0 alert |
| Leadlikeness : | 1.0 |
| Synthetic accessibility : | 1.73 |
Safety of [ 42202-95-9 ]
| Signal Word: | Danger | Class: | 6.1,8 |
| Precautionary Statements: | P260-P264-P280-P301+P330+P331+P310-P303+P361+P353+P310+P363-P304+P340+P310-P305+P351+P338+P310-P405-P501 | UN#: | 2928 |
| Hazard Statements: | H301-H311-H314-H331 | Packing Group: | Ⅱ |
| GHS Pictogram: |   | ||
Application In Synthesis of [ 42202-95-9 ]
*All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
- Upstream synthesis route of [ 42202-95-9 ]
- Downstream synthetic route of [ 42202-95-9 ]
[ 42202-95-9 ] Synthesis Path-Upstream 1~5
- 1
- [ 42202-95-9 ]
- [ 107-19-7 ]
- [ 206055-89-2 ]
Reference： [1] Journal of the Chinese Chemical Society, 2007, vol. 54, # 3, p. 643 - 652
[2] Synthesis, 2002, # 12, p. 1663 - 1668
[3] Bioorganic and Medicinal Chemistry Letters, 2011, vol. 21, # 15, p. 4652 - 4657
[4] European Journal of Medicinal Chemistry, 2017, vol. 128, p. 25 - 35
- 2
- [ 42202-95-9 ]
- [ 1018297-63-6 ]
Reference： [1] Patent: WO2013/57124, 2013, A1,
[2] Patent: US2013/172329, 2013, A1,
[3] Patent: WO2013/57124, 2013, A1,
[4] Patent: WO2013/57124, 2013, A1,
[5] Patent: WO2013/57124, 2013, A1,
[6] Patent: US2013/172329, 2013, A1,
- 3
- [ 4341-76-8 ]
- [ 42202-95-9 ]
- [ 954230-39-8 ]
| Yield | Reaction Conditions | Operation in experiment |
|---|---|---|
| 44% | With triethylamine In diethyl ether at 0 - 20℃; | Step c: 3-(4-Fluoro-phenyl)-5-methyl-isoxazole-4-carboxylic acid ethyl ester To a solution of (E)- and/or (Z)-N-hydroxy-4-fluoro-benzenecarboximidoyl chloride (15.4 g, 89 mmol) (11.1 g, 64 mmol) in diethylether (151 mL) was added ethyl 2-butynoate (7.2 g, 7.5 mL, 64 mmol) at 0° C. followed by the dropwise addition of triethylamine (7.8 g, 10.7 mL, 77 mmol) and the resulting mixture allowed to warm up to room temperature overnight. The mixture was then poured onto ice-water, and extracted with diethylether. The combined organic layers were then washed with water and brine, dried over sodium sulfate and evaporated. Purification by chromatography (SiO2, heptane:ethyl acetate=100:0 to 1:1) afforded the title compound (9.8 g, 44percent) which was obtained as an off white solid. MS: m/e=250.1 [M+H]+. |
| 44% | With triethylamine In diethyl ether at 0 - 20℃; | To a solution of (E)- and/or (Z)-N-hydroxy-4-fluoro-benzenecarboximidoyl chloride (15.4 g, 89 mmol) (11.1 g, 64 mmol) in diethylether (151 mL) was added ethyl 2-butynoate (7.2 g, 7.5 mL, 64 mmol) at 0 °C followed by the dropwise addition of triethylamine (7.8 g, 10.7 mL, 77 mmol) and the resulting mixture allowed to warm up to room temperature overnight. The mixture was then poured onto ice-water, and extracted with diethylether. The combined organic layers were then washed with water and brine, dried over sodium sulfate and evaporated. Purification by chromatography (Si02, heptane:ethyl acetate = 100:0 to 1: 1) afforded the title compound (9.8 g, 44percent) which was obtained as an off white solid. MS: m/e = 250.1 [M+H]+. |
Reference： [1] Patent: US2013/172329, 2013, A1, . Location in patent: Paragraph 0244
[2] Patent: WO2013/57124, 2013, A1, . Location in patent: Page/Page column 33
- 4
- [ 2723-42-4 ]
- [ 42202-95-9 ]
- [ 954230-39-8 ]
| Yield | Reaction Conditions | Operation in experiment |
|---|---|---|
| 2.37 g | at 20℃; for 28 h; | To a suspension of 4-fluoro-benzaldehyde oxime (1.39 g, 10.0 mmol) in DMF (10 mL) was added portionwise within 5 minutes at 15 to 20°C N-chlorosuccinimide (1.36 g, 10.0 mmol) and the resulting mixture was stirred at room temperature for 90 minutes. The yellow solution (containing N-Hydroxy-4-fluoro-benzenecarboximidoyl chloride) was then treated within 2 minutes at room temperature with a solution of ethyl-3-(l-pyrrolidino)crotonate (1.89 g, 10.0 mmol) in 5 mL of DMF and the resulting solution was stirred at room temperature for 28 hours. The mixture was diluted with water (25 mL) and subsequently extracted with ethyl acetate (4x25 mL). The combined organic layers were washed with 1 M HCl (2x25 mL) and water (2x25 mL), dried over Na2S04 and subsequently concentrated to dryness (45°C/25 mbar) to afford 2.37 g (95percent) of the title ester as a brownish solid with a purity of 100percent (by GC) and 97percent (by HPLC). |
Reference： [1] Patent: WO2013/57124, 2013, A1, . Location in patent: Page/Page column 36
- 5
- [ 42202-95-9 ]
- [ 1159600-41-5 ]
Reference： [1] Patent: WO2013/57124, 2013, A1,
[2] Patent: WO2013/57124, 2013, A1,
[3] Patent: WO2013/57124, 2013, A1,
[4] Patent: WO2013/57124, 2013, A1,
[5] Patent: WO2013/57124, 2013, A1,
[6] Patent: WO2013/57124, 2013, A1,
[7] Patent: WO2013/57124, 2013, A1,
[8] Patent: WO2013/57124, 2013, A1,
[9] Patent: WO2013/57124, 2013, A1,
[10] Patent: WO2013/57124, 2013, A1,
[11] Patent: WO2013/57124, 2013, A1,
[12] Patent: WO2013/57124, 2013, A1,
[13] Patent: WO2013/57124, 2013, A1,
[14] Patent: WO2013/57124, 2013, A1,
[15] Patent: WO2013/57124, 2013, A1,
[16] Patent: WO2013/57124, 2013, A1,
[17] Patent: US2013/172329, 2013, A1,
[18] Patent: US2013/172329, 2013, A1,
[19] Patent: US2013/172329, 2013, A1,
[20] Patent: US2013/172329, 2013, A1,
[21] Patent: US2013/172329, 2013, A1,
[22] Patent: US2013/172329, 2013, A1,
[23] Patent: US2013/172329, 2013, A1,
[24] Patent: US2013/172329, 2013, A1,
Tags: 42202-95-9 synthesis path| 42202-95-9 SDS| 42202-95-9 COA| 42202-95-9 purity| 42202-95-9 application| 42202-95-9 NMR| 42202-95-9 COA| 42202-95-9 structure
Recommend Products
Same Skeleton Products
Related Products
Categories
Chemistry
Organic Building Blocks
Benzene Compounds
benzyl
Chemistry
Organic Building Blocks
Fluorinated Building Blocks
fluorobenzene
Chemistry
Organic Building Blocks
Ketones
acetophenone
Chemistry
Organic Building Blocks
Aryls
Chemistry
Organic Building Blocks
Benzyl Chlorides
Chemistry
Organic Building Blocks
Chlorides
Chemistry
Organic Building Blocks
Oximes
Historical Records
